Immunoglobulin A Nephropathy clinical trials

Explore recruiting immunoglobulin a nephropathy clinical trials.

Recruiting immunoglobulin a nephropathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Immunoglobulin A Nephropathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)

Germany, Portugal, Italy, Spain, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Povetacicept in Adults with Immunoglobulin A Nephropathy (RAINIER).

Norway, Latvia, Hungary, Poland, Austria, Belgium +13 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Open-Label, Single-Arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatric Participants (2 to < 18 years of age) with Primary Immunoglobulin A Nephropathy (IgAN)

Spain, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Felzartamab in Adults with IgA Nephropathy (299IG301 / PREVAIL)

Greece, Portugal, Spain, Croatia, Czechia, Belgium +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN)

Netherlands, Belgium, Hungary, Spain, Austria, Poland +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy (PROTECT)

Poland, Portugal, Belgium, France, Germany, Lithuania +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Immunoglobulin A Nephropathy trials by city

Immunoglobulin A Nephropathy in Toronto Immunoglobulin A Nephropathy in Vancouver Immunoglobulin A Nephropathy in Montreal Immunoglobulin A Nephropathy in Calgary Immunoglobulin A Nephropathy in Edmonton Immunoglobulin A Nephropathy in Ottawa Immunoglobulin A Nephropathy in Winnipeg Immunoglobulin A Nephropathy in Quebec City Immunoglobulin A Nephropathy in Hamilton Immunoglobulin A Nephropathy in Kitchener Immunoglobulin A Nephropathy in London Immunoglobulin A Nephropathy in Halifax Immunoglobulin A Nephropathy in New York Immunoglobulin A Nephropathy in Los Angeles Immunoglobulin A Nephropathy in Chicago Immunoglobulin A Nephropathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease